Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension

Summary

Although the aetiology of SSc-PAH remains elusive, vascular dysfunction seems to be the initial event and statins through their vasculoprotective effect might be of value in the treatment armamentarium of PAH related to SSc. The aim was to assess the efficacy of rosuvastatin in ameliorating vascular dysfunction and in the management of SSc-related PAH.

Timeline

Start

2008-09

Primary completion

2009-07

Completion

2009-07

Drugs

Indications